| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $213,411 | 4 | 100 |
Sells | $0 | 0 | 0 |
| Young David | Pres. Research & Development | 1 | $99,289 | 0 | $0 | $99,289 |
| Ng George K | Chief Executive Officer | 1 | $69,542 | 0 | $0 | $69,542 |
| Lin Patrick | Chief Business - Strategy Off | 1 | $34,691 | 0 | $0 | $34,691 |
| Yorke Justin W | director | 1 | $9,889 | 0 | $0 | $9,889 |
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.
Over the last 12 months, insiders at Processa Pharmaceuticals, Inc. have bought $213,411 and sold $0 worth of Processa Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Processa Pharmaceuticals, Inc. have bought $177,850 and sold $2.68M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Young David (Pres. Research & Development) — $99,289. Ng George K (Chief Executive Officer) — $69,542. Lin Patrick (Chief Business - Strategy Off) — $34,691.
The last purchase of 124,500 shares for transaction amount of $99,289 was made by Young David (Pres. Research & Development) on 2025‑01‑27.
| 2025-01-27 | Young David | Pres. Research & Development | 124,500 4.3802% | $0.80 | $99,289 | -51.28% | ||
| 2025-01-27 | Ng George K | Chief Executive Officer | 87,200 3.0679% | $0.80 | $69,542 | -51.28% | ||
| 2025-01-27 | Lin Patrick | Chief Business - Strategy Off | 43,500 1.5304% | $0.80 | $34,691 | -51.28% | ||
| 2025-01-27 | Yorke Justin W | director | 12,400 0.4363% | $0.80 | $9,889 | -51.28% | ||
| 2024-02-07 | Young David | Pres. Research & Development | 21,000 0.9297% | $2.45 | $51,526 | -31.39% | ||
| 2024-02-06 | Young David | Pres. Research & Development | 20,000 0.9113% | $2.53 | $50,504 | -35.71% | ||
| 2024-02-01 | Lin Patrick | Chief Business - Strategy Off | 1,500 0.065% | $2.40 | $3,600 | -32.48% | ||
| 2024-01-31 | Lin Patrick | Chief Business - Strategy Off | 2,500 0.1069% | $2.37 | $5,925 | -33.05% | ||
| 2024-01-30 | Yorke Justin W | director | 8,000 0.3887% | $2.69 | $21,544 | -41.48% | ||
| 2024-01-30 | Ng George K | Chief Executive Officer | 10,000 0.4872% | $2.70 | $27,000 | -41.48% | ||
| 2023-06-12 | Young David | President & CEO | 40,000 0.1925% | $0.80 | $32,000 | -58.56% | ||
| 2023-04-14 | Young David | President & CEO | 20,000 0.0966% | $0.55 | $10,998 | -25.80% | ||
| 2023-04-13 | Young David | President & CEO | 20,000 0.0897% | $0.48 | $9,600 | -21.06% | ||
| 2023-04-12 | Young David | President & CEO | 20,000 0.0898% | $0.45 | $9,000 | -15.23% | ||
| 2023-04-11 | Young David | President & CEO | 20,000 0.0993% | $0.52 | $10,400 | -18.15% | ||
| 2022-05-17 | Lin Patrick | Chief Business - Strategy Off | 2,000 0.0106% | $1.59 | $3,189 | +4.23% | ||
| 2022-04-06 | Lin Patrick | Chief Business - Strategy Off | 2,000 0.0132% | $3.29 | $6,587 | -31.88% | ||
| 2022-01-27 | Sale | Yorke Justin W | director | 1,854 0.0116% | $3.30 | $6,118 | -17.73% | |
| 2021-12-14 | Lin Patrick | Chief Business - Strategy Off | 3,000 0.0194% | $4.00 | $12,000 | -25.06% | ||
| 2021-12-06 | Sale | Yorke Justin W | director | 4,200 0.0283% | $4.71 | $19,784 | -33.04% |
| Young David | Pres. Research & Development | 205405 0.7842% | $44,018.29 | 9 | 0 | <0.0001% |
| Ng George K | Chief Executive Officer | 87200 0.3329% | $18,686.96 | 2 | 0 | <0.0001% |
| Lin Patrick | Chief Business - Strategy Off | 43500 0.1661% | $9,322.05 | 10 | 0 | <0.0001% |
| Yorke Justin W | director | 12400 0.0473% | $2,657.32 | 2 | 5 | <0.0001% |
| BESSER JAMES E | 648300 2.475% | $138,930.69 | 1 | 6 | +75.7% | |
| Stanker James H | Chief Financial Officer | 36510 0.1394% | $7,824.09 | 2 | 0 | <0.0001% |
| Floyd Robert Michael | Chief Operating Officer | 28000 0.1069% | $6,000.40 | 1 | 0 | <0.0001% |
$1,138,733 | 28 | -4.94% | $5.09M | |
$47,363 | 28 | -14.61% | $4.29M | |
$63,749,694 | 24 | -12.24% | $7.91M | |
Processa Pharmaceuticals, Inc. (PCSA) | $613,181 | 18 | -20.90% | $5.61M |
$1,556,551 | 15 | -25.43% | $5.82M | |
$742,412 | 14 | -50.36% | $5.14M | |
$139,855 | 11 | -32.84% | $5.16M | |
$111,748 | 9 | -47.72% | $5.01M | |
$159,974 | 7 | -18.60% | $4.5M | |
$40,324 | 6 | 31.82% | $7.69M | |
$1,028,395 | 4 | -11.91% | $7.65M | |
$149,778 | 4 | -45.16% | $7.2M | |
$726,438 | 4 | -72.85% | $5.22M | |
$76,299 | 4 | 11.60% | $6.74M | |
$14,530 | 3 | 62.23% | $4.44M | |
$4,423 | 2 | 3.27% | $6.83M | |
$7,699,992 | 2 | -74.95% | $8.35M | |
$44,529 | 2 | -30.33% | $8.57M | |
$1,049,630 | 1 | -74.91% | $4.65M |
| Increased Positions | 5 | +71.43% | 111,677 | +112.88% |
| Decreased Positions | 2 | -28.57% | 39,823 | -40.25% |
| New Positions | 2 | New | 99,229 | New |
| Sold Out Positions | <1 | Sold Out | 31,971 | Sold Out |
| Total Postitions | 10 | +42.86% | 170,789 | +72.63% |
| Hrt Financial Lp | $7.00 | 0.64% | 31,971 | +31,971 | New | 2024-12-31 |
| Vanguard Group Inc | $6.00 | 0.49% | 24,433 | 0 | 0% | 2024-12-31 |
| Geode Capital Management, Llc | $5.00 | 0.44% | 21,982 | +2,289 | +11.62% | 2024-12-31 |
| Miracle Mile Advisors, Llc | $2.00 | 0.2% | 10,000 | 0 | 0% | 2025-03-31 |
| Ubs Group Ag | $2.00 | 0.16% | 7,908 | +7,387 | +1,417.85% | 2024-12-31 |
| Tower Research Capital Llc (Trc) | $1.00 | 0.05% | 2,462 | -1,178 | -32.36% | 2024-12-31 |
| Wells Fargo & Company/Mn | $0 | <0.01% | 154 | 0 | 0% | 2024-12-31 |
| Bank Of America Corp /De/ | $0 | <0.01% | 25 | +<1 | +4.17% | 2024-12-31 |